Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Annexon (Nasdaq: ANNX) granted an inducement equity award to a new non-executive employee under its 2022 Employment Inducement Award Plan, approved December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
The award is an option to purchase 19,000 shares, with a 10-year term, an exercise price of $4.91 per share (closing price on December 15, 2025, the grant date), and a standard four-year vesting schedule: 25% vesting after one year and the remainder vesting monthly at 1/48th thereafter, subject to continued service.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: NMRA -5.13%, MNPR -3.64%, OMER -2.83%, while LCTX +2.92% and ALEC 0%, suggesting no clear sector-wide trend tied to this routine grant.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 14 | Equity offering close | Negative | +11.4% | Closed underwritten equity offering with full underwriter option exercise. |
| Nov 12 | Offering priced | Negative | -4.4% | Priced $75M public offering of common stock and pre‑funded warrants. |
| Nov 12 | Offering proposed | Negative | -4.4% | Commenced proposed $75M public offering using existing shelf registration. |
| Nov 10 | Earnings and pipeline | Positive | -0.3% | Reported Q3 2025 results, cash runway and late‑stage clinical milestones. |
| Aug 27 | Investor conferences | Neutral | -1.9% | Announced participation in September healthcare investor conferences. |
Recent news shows mixed alignment: two public offering announcements and one earnings update aligned with expected sentiment, while one offering close and the Q3 update saw divergent price reactions.
Over the last several months, Annexon issued multiple equity offerings and reported Q3 2025 results. The company priced and closed an underwritten public offering in mid‑November 2025, with gross proceeds of about $86.25M, following a proposed and then priced $75.0M raise. Q3 2025 results highlighted late‑stage programs and a cash position of $188.7M. Earlier, Annexon announced participation in investor conferences. Today’s inducement option grant fits into this backdrop of active capital raising and advancing late‑stage programs.
Market Pulse Summary
This announcement details a standard Nasdaq‑compliant inducement option grant of 19,000 shares with a 10‑year term and a market-based $4.91 exercise price, vesting over 4 years. It follows a period of active capital raising and advancing late‑stage programs. Investors may watch how ongoing financings, insider activity, and future clinical or regulatory milestones interact with equity-based compensation over time.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. Not financial advice.
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
The new non-executive employee received an option to purchase 19,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to
About Annexon
Annexon, Inc. (Nasdaq: ANNX) is developing the next generation of complement inhibitors to stop neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss in a host of diseases. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade before it starts. Our pipeline spans three diverse therapeutic areas – autoimmunity, neurodegeneration and ophthalmology – and includes targeted investigational drug candidates designed to address the unmet needs of nearly 10 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
What did Annexon (ANNX) grant on December 15, 2025?
What is the term and exercise price of the Annexon (ANNX) inducement option?
How does the Annexon (ANNX) option vest?
Under what rule was the Annexon (ANNX) inducement approved?
Which plan governs the Annexon (ANNX) inducement award?
What price was used to set the Annexon (ANNX) option exercise price?
